TSS
ALGS icon

Two Sigma Securities’s Aligos Therapeutics ALGS Stock Holding History

Two Sigma Securities’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-590
Closed -$9.79K – 2915
2023
Q4 		$9.79K Buy
+590
New +$10.1K ﹤0.01% 2818

Other funds holding ALGS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
ACP
Altitude Crest Partners Stamford, Connecticut $234M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Two Sigma Securities's ALGS Position: Q1 2024 in Review

Two Sigma Securities sold out of Aligos Therapeutics (ALGS) in Q1 2024, closing a stake of 590 shares — an estimated $9.79K sold.

Two Sigma Securities first reported a position in ALGS in Q4 2023 and held it in 1 quarter. The position peaked at $9.79K in Q4 2023. 48 funds tracked by Wall St. Rank hold ALGS as of Q1 2024.

  • Two Sigma Securities reported no remaining Aligos Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Two Sigma Securities sold 590 Aligos Therapeutics shares in Q1 2024, an estimated $9.79K.
  • Two Sigma Securities first reported a position in Aligos Therapeutics in Q4 2023 and held it in 1 quarter.
  • Two Sigma Securities's Aligos Therapeutics position peaked at $9.79K in Q4 2023.
  • 48 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q1 2024.

Based on Two Sigma Securities's 13F filing for Q1 2024, filed 15 May 2024.